Depression is one of the most serious health conditions affecting people today. Although many people think depression simply means feeling sad, the illness can be much more severe and long-lasting.
Major depressive disorder can affect emotions, sleep, energy, appetite, memory, concentration, and even physical health.
Some people with depression struggle to get out of bed, go to work, or enjoy activities they once loved. Others experience constant hopelessness, emotional numbness, or thoughts of suicide.
Families and caregivers are often deeply affected as well because severe depression can place enormous strain on relationships and daily life.
Modern antidepressants have helped many patients over the past few decades, but doctors have long faced a difficult problem: a large number of people do not improve enough with standard treatments.
Researchers estimate that about one in three adults with major depressive disorder continue to suffer even after trying at least two different antidepressant medications. These patients are considered to have treatment-resistant depression, a condition that remains one of the biggest challenges in psychiatry.
For years, scientists have searched for better ways to help these patients. Now, researchers from UConn School of Medicine and several major universities, including Harvard, Yale, and the University of Toronto, have reported important new findings that may change how doctors treat severe depression.
Their research was published in the journal JAMA Psychiatry and focused on two different treatment approaches that use existing medications in newer ways.
The first study examined ketamine, a drug that has received growing attention in mental health research over recent years.
Ketamine was originally created as an anesthetic used in hospitals during surgery because it works quickly and safely for many patients. However, scientists later discovered something surprising: ketamine appeared to rapidly improve symptoms of depression in some people.
This discovery was unusual because traditional antidepressants often require several weeks before patients notice improvement. For people experiencing severe depression or suicidal thoughts, waiting weeks for relief can be dangerous.
Researchers became especially interested in ketamine because some patients reported feeling better within hours or days after treatment. This rapid effect raised hopes that ketamine could become a valuable option for people in mental health crisis situations.
In the new study, researchers reviewed 26 earlier randomized clinical trials comparing intravenous ketamine with placebo treatments or control groups. Intravenous treatment means the drug is delivered directly into the bloodstream through an IV drip.
The scientists found that ketamine clearly outperformed placebo treatments during the first few days after treatment. Patients receiving ketamine often showed rapid improvements in mood and depressive symptoms.
Perhaps most importantly, ketamine appeared highly effective at quickly reducing suicidal thinking in people facing immediate risk.
Doctors say this may be one of ketamine’s most valuable features because suicidal crises require fast action. Standard antidepressants usually do not act quickly enough in emergency situations.
However, the researchers also found important limitations. The antidepressant effects of ketamine became weaker after a few weeks. This means ketamine may provide short-term relief without necessarily solving long-term depression problems by itself.
The study also found that intravenous ketamine worked similarly to esketamine, a related nasal spray medication already approved by the US Food and Drug Administration for treatment-resistant depression.
The second study focused on another strategy: combining antidepressants with antipsychotic medications.
Antipsychotic drugs are usually associated with conditions like schizophrenia or bipolar disorder, but some doctors also prescribe them alongside antidepressants for difficult depression cases.
Researchers reviewed 22 studies that examined how well these medication combinations reduced depressive symptoms and how often patients stopped treatment because of side effects.
Several antipsychotic medications appeared to improve depression symptoms when added to antidepressants. But one drug, lumateperone, produced mixed results. It seemed especially effective for reducing symptoms, but many patients also stopped taking it because of unpleasant side effects.
This finding highlights an important issue in psychiatry. Many powerful medications can improve symptoms while also causing side effects that some patients find difficult to tolerate. Doctors often have to balance effectiveness with safety and comfort.
The researchers believe these findings may help doctors better guide treatment decisions for patients with moderate to severe depression who do not respond to standard antidepressants.
Dr. T. Greg Rhee from UConn School of Medicine explained that alternative treatment approaches are urgently needed because many patients continue suffering despite repeated treatment attempts.
The studies also reflect broader changes happening in depression research. Scientists are increasingly learning that depression may involve many different brain systems rather than one single chemical imbalance. This may explain why some patients respond to certain treatments while others do not.
Researchers are now exploring treatments that affect different pathways in the brain, including inflammation, stress responses, brain connectivity, and glutamate signaling, which ketamine influences differently from standard antidepressants.
The researchers plan to continue studying these treatments in larger population studies to better understand long-term safety, effectiveness, and which patients are most likely to benefit.
Mental health experts caution that ketamine and antipsychotic medications are not risk-free.
Ketamine can sometimes cause temporary dissociation, unusual perceptions, or blood pressure changes, while antipsychotic drugs may lead to weight gain, sedation, or movement-related side effects. Careful medical supervision is therefore very important.
Still, the findings offer hope for patients who have struggled for years without finding relief. Treatment-resistant depression can be devastating, and even partial improvement may greatly improve quality of life for patients and families.
The studies published in JAMA Psychiatry suggest that future depression care may become far more individualized. Instead of giving every patient similar medications, doctors may eventually choose treatments based on each person’s biology, symptoms, and response patterns.
After reviewing the findings, the research appears valuable because it draws evidence from many previous studies rather than isolated experiments. This gives the conclusions stronger scientific support.
The ketamine results are especially promising for emergency psychiatric care because rapid reduction of suicidal thoughts could save lives. However, the short duration of benefits also shows that more work is needed to create lasting improvements.
The medication combination study also demonstrates both progress and caution. Some antipsychotic combinations may help people with severe depression, but side effects continue to limit treatment success for some patients.
Overall, the research highlights that depression treatment is entering a new phase where doctors are exploring faster, more targeted, and more personalized therapies for patients who have not benefited from traditional antidepressants.
If you care about depression, please read studies about how dairy foods may influence depression risk, and B vitamins could help prevent depression and anxiety.
For more information about mental health, please see recent studies that ultra-processed foods may make you feel depressed, and extra-virgin olive oil could reduce depression symptoms.
Source: UConn School of Medicine.
